ALK has been extensively studied in non‐small cell lung cancer, and the FDA has also approved five ALK inhibitors—alectinib, bugatinib, seretinib, clozotinib, and lorlatinib—for non‐small cell lung cancer with abnormal ALK expression [19, 20]. Here, ALK is linked to lung cancer.